Trial Profile
A Prospective, Multi-Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Zotarolimus
- Indications Acute coronary syndromes; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms ReCre8
- 01 Feb 2023 Results (n=302) of Subanalysis, assessing long-term performance of two contemporary drug-eluting stents in a diabetic population, published in the Catheterization and Cardiovascular Interventions
- 02 Jan 2019 Results published in the Circulation
- 15 Feb 2018 Trial design published in the Catheterization and Cardiovascular Interventions